Results 131 to 140 of about 85,259 (288)

Integrated scFv identification and CAR T cell generation for AML targeting in vivo

International Journal of Cancer, EarlyView.
What's New? Acute myeloid leukemia (AML) is a rapidly progressing blood cancer. Advancing chimeric antigen receptor (CAR) T cell therapies, particularly through rapid translation of single chain variable fragment (scFv) discovery into CAR constructs, may improve clinical outcomes, especially the development of patient individualized CAR T cells.
Yi Liu, Annika Lauk, David Sedloev, Josephine Brysting, Ela Cetin, Chunan Liu, Maximilian Mönnig, Thomas Luft, Haiyang Yun, Michael Schmitt, Tim Sauer, Fengbiao Zhou, Christian Rohde, Carsten Müller‐Tidow   +13 more
wiley   +1 more source

New insights into applications of base editor in hereditary disorders

Interdisciplinary Medicine, EarlyView.
Abstract Hereditary disorders are a group of diseases caused by genetic mutations or chromosomal variations. Although the incidence of each genetic disorder is relatively low, patients affected by the disease generally experience a range of severe symptoms, including blindness, disability, and even premature death. In addition, the available treatments
Maoping Cai, Linhui Zhang, Liqing Li, Yue Liu, Canbin Lv, Yan Shi, Jianyuan Zhao, Dingwei Ye, Yuanyuan Qu   +8 more
wiley   +1 more source

The study of pharmacodynamics of a medicine based on humanized monoclonal antibodies against IL-17 in rabbit model of antigen-induced arthritis

Биопрепараты: Профилактика, диагностика, лечение, 2018
The present article contains scientific data on the assessment of specific activity of therapeutic humanized monoclonal antibodies against IL-17 in rabbit model of antigen-induced arthritis.
A. A. Nedorubov, A. V. Grachev, M. A. Varavko, E. L. Morozova   +3 more
doaj  

Neuroinflammation drives apathy in cancer cachexia

Cancer Communications, EarlyView.
Bingjun Ha, Xuetao Cao
wiley   +1 more source

Fertility and Early Embryonic Development Toxicity of hzVSF‐v13 in Sprague–Dawley Rats

Journal of Applied Toxicology, EarlyView.
ABSTRACT Humanized virus suppressing factor–variant 13 (hzVSF‐v13), a monoclonal IgG4 antibody, is a potential therapeutic candidate for COVID‐19. Although fertility and embryonic developmental toxicity studies are crucial for the safety evaluation of new drugs, the toxicological profile of hzVSF‐v13 remains unexplored.
Ji‐Seong Jeong, Sang‐Yun Kim, Jinsoo Lee, Seung‐Jin Lee, Onju Ham, Woojin Kim, Wan‐Jung Im, Sungman Park, Kyong‐Cheol Ko, Jong‐Choon Kim, Yong‐Bum Kim   +10 more
wiley   +1 more source

Development of a step‐gradient simulated moving bed process for the polishing of monoclonal antibodies with anion exchange chromatography

Journal of Chemical Technology &Biotechnology, EarlyView.
Abstract BACKGROUND In recent years, biopharmaceutical applications in medicine have seen explosive growth and the need for efficient, rapid and inexpensive purification of these targets is the topic of tremendous research and development. The need to improve process efficiency has been an active area of investigation due to the tremendous potential ...
Yasmina MJ Harsy, Jonas Wege, Anthony Grabski, Romain Dabre, Egbert Müller, Carsten‐René Arlt   +5 more
wiley   +1 more source

Successful Treatment of Spesolimab in a Haemodialysis Patient With Acutely Flaring Generalised Pustular Psoriasis

JEADV Clinical Practice, EarlyView.
Capsule Summary Generalised pustular psoriasis is one of the severe dermatological disorders. The use of biologics in psoriatic patients with end‐stage renal disease is rare, and the safety information on biologics treatment in such patients is limited.
Yasuyuki Fujita, Sota Itamoto, Akihiro Orita, Kunihiro Kawashima, Satoko Shimizu   +4 more
wiley   +1 more source

The use of immunoglobulins and monoclonal antibodies against COVID-19

Вопросы вирусологии
Introduction. When a new disease occurs, one of the most affordable remedies is drugs containing specific antibodies to this infectious agent. The use of such drugs is aimed at reducing the amount of the pathogen in the macroorganism and the associated ...
Elena E. Popadyuk, Tatyana E. Sizikova, Aleksey L. Khmelev, Mikhail A. Timofeev, Vitaliy N. Lebedev, Sergey V. Borisevich   +5 more
doaj   +1 more source

Successful Lebrikizumab Therapy in Two Patients With Atopic Dermatitis Resistant to Multiple Therapies

JEADV Clinical Practice, EarlyView.
ABSTRACT The treatment landscape for moderate‐to‐severe atopic dermatitis (AD) has evolved significantly with the introduction of novel targeted therapies addressing specific pathogenic mechanisms of the disease. Despite this therapeutic revolution, a proportion of patients experience intolerance and/or inadequate response to multiple lines of ...
Elena Ippoliti, Niccolò Gori, Benedetta Ambrosio, Giulia Coscarella, Maria Vittoria Cannizzaro, Ketty Peris   +5 more
wiley   +1 more source

Pilot Study of Tildrakizumab in the Treatment of Stable Non‐Segmental Vitiligo

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Treatment for vitiligo is limited, with variable efficacy, and can be time‐consuming or expensive. Recent developments within biologic therapy have demonstrated promising results with managing chronic autoimmune conditions. Objectives To evaluate the efficacy of tildrakizumab in inducing repigmentation in vitiligo.
Henry Lee, Timothy L. Cowan, Cheng Huang, Anna Wilson, Ben Koszegi, Corey Stone, Jade Ng, Sera Sarsam, Hossein Akbarialiabad, Joslin S. Johal, Oliver G. C. Murrell, Richard A. Wittal, Dédée F. Murrell, Benjamin S. Daniel   +13 more
wiley   +1 more source